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Abstract 
The yeast plasma membrane proton pumping ATPase (H+-ATPase) was investigated as a potential molecular target for antifungal 
drug therapy by examining the inhibitory effects of the sulfhydryl-reactive reagent omeprazole on cell growth, glucose-induced medium 
acidification and H+-ATPase activity. Omeprazole inhibits the growth of Saccharomyces cerevisiae and the human pathogenic yeast 
Candida albicans in a pH dependent manner. Omeprazole action is closely correlated with inhibition of the H +-ATPase and is fungicidal. 
Glucose-dependent medium acidification is correspondingly blocked by omeprazole and appears to require the H+-ATPase to proceed 
through its reaction cycle. A strong correlation is observed between inhibition of medium acidification and H ÷-ATPase activity in plasma 
membranes i olated from treated cells. The inhibitory properties of omeprazole are blocked by pre-treatment of activated drug with 
/3-mercaptoethanol, which is consistent with the expected formation of a sulfhydryl-reactive sulfenamide derivative. Mutagenesis of the 
three putative membrane sector cysteine residues (C148S, C312S, C867A) in the S. cerevisiae H÷-ATPase suggests that covalent 
modification of the conserved C148 residue may be important for inhibition of ATPase activity and cell growth. Other mutations (M128C 
and G I58D/G156C) mapping near C 148 support he importance of this region by modulating omeprazole inhibition of the H +-ATPase. 
These findings suggest that the plasma membrane H+-ATPase may serve as an important molecular target for antifungal intervention. 
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1. Introduction 
Fungal disease primarily occurs in humans when natural 
barriers to infection, such as the skin, mucosal surfaces, 
the immune system or competition with the endogenous 
microflora are compromised [1]. While superficial infec- 
tions of mucosal surfaces are readily treated, disseminated 
infections are frequently life-threatening because the pa- 
tient is usually debilitated and because of the limited 
efficacy and toxic side-effects of existing antifungals. 
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Novel drug targets are required so that new classes of 
antifungal drugs can be developed. The plasma membrane 
H+-ATPase of yeast is an essential enzyme that may 
represent an important new target [2]. It is a P-type ion 
translocating ATPase, a diverse class of ion pumps found 
in higher and lower eukaryotes, and many prokaryotes. 
Many of these enzymes perform a critical physiological 
function by maintaining electrochemical ion gradients 
across the plasma membrane of their respective cells. The 
binding of ATP within a cytoplasmic domain results in the 
formation of an aspartyl-phosphate intermediate that initi- 
ates a series of conformational intermediates leading to the 
stoichiometric movement of an ion(s) across the mem- 
brane. This fundamental role and the fact that these mem- 
brane-spanning enzymes have exposed extracellular do- 
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mains have been key factors in the development of clini- 
cally important therapeutics which target hese enzymes. 
The Na+,K+-ATPase, which is inhibited by ouabain 
and the cardiac glycosides [3], and the gastric H+,K +- 
ATPase, which is inhibited by omeprazole [4] and a range 
of K+-competitive compounds including SCH28080 [5], 
are currently the two most important pharmacological t r- 
gets among the P-type ATPases. The interaction of thera- 
peutic agents with these targets is known to occur from 
outside the cell but a detailed understanding of their 
mechanism of inhibitory action is just emerging [3-6]. 
These inhibitors block the cytoplasmic atalytic activity 
and interact with the enzyme most favorably during the E 2 
phase of the reaction cycle [3,5]. Several cell surface 
amino acid residues have been implicated in the interaction 
between ouabain and the cej-subunit of the Na+,K +- 
ATPase. They include two carboxyl groups at the edges of 
the turn between transmembrane s gments HI and H2 
[7-9], a proline in the middle of the HI-H2 turn [8], 
membrane mbedded cysteine and tyrosine residues in H1 
[10-12], aromatic groups in the extracytoplasmic turn 
between transmembrane segments 3 and 4 [3,13] and, most 
recently, an arginine residue located in the extracytoplas- 
mic turn between transmembrane s gments H7 and H8 
[1 ! ]. Although many of these residues or regions affect the 
overall affinity of the enzyme for ouabain, or were identi- 
fied on the basis of photoaffinity labeling studies, their 
precise role(s) in the interaction between ouabain and the 
Na+,K+-ATPase has yet to be defined. 
Covalent binding of the photoaffinity analog MeDA- 
ZIP + to the gastric H+,K+-ATPase implicated F124, near 
the C-terminal end of transmembrane s gment H! and 
D136, near the N-terminal end of transmembrane s gment 
H2, in the binding of SCH28080 to the enzyme [14,15]. 
This led to a molecular model of the SCH28080 H1-H2 
complex, in which the inhibitor interacts with the extracel- 
lular face of the transmembrane loop structure [14,15]. The 
highly effective anti-ulcer drug omeprazole is known to 
rapidly and selectively covalently react with cysteine 
residues following acid activation to a sulfenamide; how- 
ever, labeling of the H+,K+-ATPase by omeprazole has 
been problematic. Morii et al. [16] first reported that the 
sulfenamide interacted with an externally located cysteine 
in the N-terminal half of the enzyme. More recently, 
Besancon et al. [4] reported that omeprazole labeled C813 
and C822 in the external turn between transmembrane 
segments H5 and H6 and possibly C892 at the end of 
transmembrane segment H7. Shin et al. [6] used pantopra- 
zole, a more stable chemical congener of omeprazole, to 
covalently modify only C813 and C822, suggesting that 
C892 may not be essential for omeprazole inhibition of the 
ATPase. If C813 and C822 are indeed the critical residues 
modified by omeprazole, it remains to be seen how this 
modification leads to enzyme inactivation. 
Genetic and biochemical studies of the yeast plasma 
membrane H+-ATPase have shown that the region linking 
transmembrane s gments 1 and 2 is highly conformation- 
ally active [17-20]. The equivalent region in the gastric 
H+,K+-ATPase is also believed to undergo a conforma- 
tional change during phosphorylation [21]. Mutations in 
this region of the yeast H+-ATPase are known to alter the 
kinetic properties of the enzyme including the gma x and 
K m for ATP hydrolysis [17,18]. The effects of such muta- 
tions are therefore communicated to the cytoplasmic active 
site, either by conformational interaction or by altering the 
kinetic states of intermediates required for the normal 
reaction cycle of the enzyme. Many of these mutations 
also confer growth resistance to hygromycin B [17-20,22- 
24], which is thought o be associated with a defect in the 
ability of the H+-ATPase to generate an hyperpolarized 
membrane potential [23,25]. In addition, several mutations 
in the region are either strongly selected against in het- 
erozygous diploid cells or give recessive lethal mutations 
in haploid progeny, indicating that the modified residues 
may be essential for enzyme structure/function a d cell 
growth/viability [19,20]. Taken together, such observa- 
tions suggest that the first transmembrane loop of the yeast 
plasma membrane ATPase has the attributes of a useful 
inhibitory target site [2]. Given the urgent need to develop 
new classes of antifungal agents and the fact that the 
fungal plasma membrane ATPase is an essential enzyme 
which can control the rate of cell growth [26,27], our 
research as focused on the properties of the extracytoplas- 
mic and transmembrane regions of the yeast ATPase. 
The development of the plasma membrane H+-ATPase 
as a molecular target for antifungal drug therapy requires 
the demonstration that inhibition of enzyme activity corre- 
lates with cessation of cell growth. Furthermore, drugs 
which target extracytoplasmic regions of the H+-ATPase 
are highly desirable since they do not need to enter the 
cell, thus avoiding most cellular pump-based resistance 
mechanisms. We therefore chose omeprazole, an acid- 
activated sulfhydryl-scavenging reagent [28] which can be 
effectively localized to the extracellular portion of the cell, 
to modify and inhibit the yeast plasma membrane ATPase 
in vivo. This approach was also based on the presence of 
two conserved cysteine residues near the cell surface of the 
ATPase [2] as well as the ability of yeast cells growing in 
glucose medium to maintain an acidic extracellular milieu. 
We have shown that omeprazole inhibits the growth of 
Saccharomyces  ceret,isiae and the human pathogenic yeast 
Candida albicans in a pH-dependent manner that is consis- 
tent with the acid-activation profile of the drug [29]. 
Omeprazole action is fungicidal and inhibition of cell 
growth corresponds well with inhibition of both proton 
pumping, determined in whole cells, and H+-ATPase ac- 
tivity, measured in isolated plasma membranes derived 
from treated cells. Genetic probing suggests that covalent 
modification of C148 in transmembrane s gment 2 is 
important for inhibition of enzyme function and cell 
growth. The potential of the H+-ATPase as a molecular 
antifungal target is discussed. 
B.C. Monk et al. / Biochimica et Biophysiczl Acta 1239 (1995) 81 90 83 
2. Materials and methods 
2.1. Yeast strains and cell culture 
The yeast strains used in this study, along with their 
phenotypic haracteristics are described in Table 1. All 
strains are isogenic derivatives of Saccharomyces cere- 
cisiae wild type strain Y55 (HO gal3 MALl SUCI). The 
control strain SN236 (HO ade6-1 trp-5-1 leu2-1 lysl-I 
ura3-1 PMAI::URA3) [17] was made by selecting a leu 
URA spore from an SH122 derivative in which the LEU2- 
disrupted pmal gene was replaced with PMAI:URA3. 
Strain C148S was obtained from the C148S $368F double 
mutant by transforming this mutant with a 4.2 kb Pc, uII- 
HindIII fragment of PMAI:URA3, thereby reverting to 
wild type the $368F mutation [18]. Strain G158D/G156C 
was obtained as a pH resistant revertant of G158D [30]. 
The Candida albicans strains used in this study was 
ATCC10261, ATCC23187 and B311. Cells were grown in 
YPD (1% yeast extract, 2% peptone, 2% dextrose) at pH 
5.5 or in medium adjusted to the indicated pH with 
concentrated HC1. 
Table l 
Phenotypes of wild type and pmal mutant strains 
Strain Phenotype ~
HygB low pH 
SN236 (wt) S R 
C148S R R 
C312S S R 
C867A S R 
MI28C R S 
M 128A Recessive lethal 
G156C, GI58D b R R 
Growth resistance (R) or sensitivity (S) to YEPD solid media at pH 5.0 
containing 0.57 mM hygromycin B (HygB) or media adjusted to pH 2.5. 
b Phenotypic revertant of GI58D (hygB', low pH ~) [31]. 
measured on the Elisa readers and the true absorbance 
values determined by a spectrophotometer. Blanks contain- 
ing omeprazole but no cells were included to take into 
account he background contribution (A59 0 ..... or  A620n m < 
0.05) of acid-activated omeprazole. All readings were in 
duplicate or triplicate, giving absorbance readings within 
5% of each other. 
2.2. Site-directed mutagenesis 2.4. Glucose-induced medium acidification 
Site-directed pmal mutants were constructed in vectors 
pSN54/57, essentially as described by Na et al. [17]. To 
obtain isogenic pmal mutants a 6.1 kb linear HindIII 
DNA fragment, containing URA3 inserted into the BgllI 
site in the 3'-nontranslated portion of PMA1, was excised 
from each reconstituted pSN57 vector and was used to 
transform yeast strain SH122 (HO ade6-1 trp5-1 leu2-1 
lysl-I ura3-1 pmalA:: EU2 / PMA1) [18]. Ura leu trans- 
formants were sporulated and dissected, and the growth 
phenotypes of each dissected URA colony determined. All 
pmal mutants (Table 1) were assayed for growth on YPD 
medium at pH 5.0 containing 0.57 mM hygromycin B and 
on YPD medium adjusted to pH 2.5 with 1 M HCI [24]. 
2.3. Drug challenge growth assays 
Cells were grown to mid-log phase (A595n m ~ 5) on 
YPD medium and diluted to an A595n m ~ 0.2 in YPD 
medium at the pH used for subsequent growth. Omepra- 
zole (145 mM in 90% DMSO) was either added directly to 
YPD medium at the required pH or acid-activated for 1 h 
in the presence of 0.1 M HCI prior to addition. Growth 
assays were conducted in sterile flat-bottomed 96 well 
microtitre plates containing 200 /xl of YPD per well. The 
cells were agitated on a gyratory shaker at 150 rpm for 
20-24 h at 30°C and the growth of the cultures was 
measured using either a SLT Elisa reader (SLT Labinstru- 
ments, Research Triangle Park) or an EAR 340 microtitre 
plate reader (SLT Instruments, Austria). Absorbance mea- 
surements were made at either 590 or 620 nm, with about 
a 10-fold difference between absorbance 'unit' readings 
Cells were grown to late log phase (A595n m ~ 5) in 30 
ml of YPD medium and harvested by centrifugation at 
3500 × g for 10 min. The culture was washed once with an 
equal volume of distilled water and once with an equal 
volume of 50 mM KC1, pH 4.5. The cells were fully 
carbon starved by incubation overnight at 4°C in 15 ml of 
50 mM KCI, pH 4.5, recovered by centrifugation and 
concentrated about 20 × in 50 mM KCI, pH 4.5. The 
concentrated cells were diluted to A595n m = 8.3 in 1.8 ml 
of reaction medium (3 ml stirred cuvette) containing 50 
mM KCI, pH 4.5, the test reagents added and the mix 
adjusted to pH 4.5. After a 10 min preincubation, medium 
acidification was initiated by adding 0.2 ml of 20% glu- 
cose. The pH of the medium was determined using a 
rapidly responding pH electrode (Microelectrodes). 
Omeprazole is essentially fully active after 20 rain expo- 
sure to 0.1 M HCI in DMSO and the drug is about 50% 
inactivated after about 8 h under these conditions. All 
experiments on proton pumping were conducted within 2 h 
following l h of acid-activation. 
For experiments requiring comparative measurements 
between relative proton pumping and the ATPase activities 
associated with plasma membranes, the volume of the 
assay was scaled up 50-fold, After a 30 min incubation 
with drug, the cells were pelleted by centrifugation at4°C, 
and washed twice with buffer consisting of 50 mM Tris 
pH 7.0, 0.5 mM EDTA, 2% glucose, 0.5 mM reduced 
glutathione and 1 mM PMSF. The cells were lysed in a 
French pressure cell, the pH adjusted to 7.0 with KOH and 
the plasma membranes purified by sucrose gradient centrif- 
ugation, as described by Monk et al. [31]. 
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2.5. ATPase and other biochemical assays 
Microscale plasma membrane ATPase assays were con- 
ducted as described by Monk et al. [31]. The treatment of 
H+-ATPase in vitro with omeprazole was performed in a 
stabilization buffer (100 mM sodium citrate, pH 3.5, 40% 
glycerol and 100 mM KC1) which minimized pH-depen- 
dent enzyme-inactivation during a 5 rain pretreatment with 
the drug. All in vitro experiments were performed with 
deoxycholate-treated plasma membranes [25] since native 
plasma membranes rapidly precipitated under these condi- 
tions. 
Protein was estimated using the Bio-Rad microassay 
using bovine 7-globulin as standard [32]. 
3. Results 
3.1. Inhibition of fungal cell growth by omeprazole 
Omeprazole is an acid-activated reagent hat forms a 
reactive sulfenamide derivative capable of modifying free 
sulfhydryl groups [28,29]. The growth of wild type strains 
of Saccharomyces cerevisiae (SN236) and Candida albi- 
cans (ATCC 10261) was significantly inhibited by omepra- 
zole in a dose- and pH-dependent manner. Fig. 1 shows 
that Saccharomyces was more sensitive to growth inhibi- 
tion by omeprazole than its Candida counterpart. At pH 
3.0, 0.43 mM omeprazole was required to fully inhibit 
growth of SN236 whereas approximately twice as much 
omeprazole was required for ATCCI0261 (Fig. 1A,B.) 
The growth of SN236 was maximally inhibited by 0.22 
mM omeprazole at pH 2.5 and 3.0. Between pH 3.0 and 
pH 4.5, omeprazole inhibition declined by about 75% for 
each unit increase in pH. The growth of C. albicans strain 
ATCCI0261 was generally 2-3-times less sensitive than 
S. cereuisiae strain SN236 at pH 3.5 and below, and was 
essentially unaffected by the drug at pH 4.0 and above 
(Fig. 1B). Similar behavior was observed for other Can- 
dida wild type strains (ATCC23187 and B311). The pH- 
dependence for omeprazole-mediated growth inhibition of 
both S. cereuisiae and C. albicans is consistent with the 
acid-activated properties of omeprazole which result in the 
formation of a highly reactive sulfenamide. 
The formation of this specific sulfenamide species from 
acid-treated omeprazole can be monitored at a wavelength 
of 355 nm [29]. The conversion is relatively rapid with a 
T1/2 for omeprazole activation of ~ 7 min (data not 
shown). Acid-activated omeprazole and untreated omepra- 
zole were similarly effective at inhibiting growth of SN236 
below pH 3.5, while inhibition of growth at pH 4.0 and 4.5 
was enhanced by acid activation (Fig. 2A and Fig. 1A). 
Acid-activated omeprazole did not inhibit growth at pH 
5.0. The sulfenamide is unstable at pH > 4.0, rapidly 
generating several inactive derivatives [29]. Pre-treatment 
of acid-activated omeprazole with a 70% excess of either 
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Fig. 1. The pH-dependence for inhibition of yeast growth by omeprazole. 
The pH-dependence for omeprazole-induced inhibition of growth by (A) 
S. cerevisiae (SN236) or (B) C. albicans (ATCC10261) was determined 
in 96 well microtitre plates, as described in Section 2. Growth (A620, m) 
was determined after 24 h at pH 2.5 to 5.5, as indicated. 
2-mercaptoethanol or reduced glutathione blocked the ac- 
tion of the drug, consistent with the sulfenamide acting as 
the inhibitor of growth (Fig. 2B). The sulfhydryl reagents 
(1.5 mM) and the carrier DMSO (0.8%) had no effect on 
growth. Preincubation of omeprazole with a slight excess 
of the two sulfhydryl reagents in YPD medium at pH 3.5 
also substantially blocked (> 80%) omeprazole-dependent 
inhibition of growth (data not shown). The growth in- 
hibitory effect of the sulfenamide was blocked by pretreat- 
ment of acid-activated omeprazole in DMSO with increas- 
ing amounts of 2-mercaptoethanol i  a stoichiometric man- 
ner (Fig. 2C). 
3.2. Omeprazole action is fungicidal 
Omeprazole was fungicidal for cells under conditions 
that inhibited cell growth (pH 3.5 medium and reagent 
concentrations > 0.43 mM) (Fig. 3), Omeprazole at 0.80 
mM killed greater than 95% of all cells after 24 h. Cell 
viability was unaffected by 1 h of exposure but was 
substantially reduced by 6 h exposure to 0.43-0.80 mM 
omeprazole (data not shown). At lower omeprazole con- 
centrations (0.22 mM) growth rates were reduced but cell 
viability was only modestly impaired. Since the sulfen- 
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Fig. 2. The sulfenamide of omeprazole affects growth of S. cerecisiae. 
(A) The pH-dependence for inhibition of S. cerecisiae growth by acid- 
activated omeprazole. Assays were conducted in 96-well microtitre plates, 
as described in Section 2 with strain SN236. Growth was determined after 
24 h. Values for medium pH are indicated on the figure. (B) Treatment of 
acid-activated omeprazole with sulfhydryl reagents. Omeprazole (Om) 
(50 mg/ml,  0.145 mM in 90% DMSO) was acid activated for 1 h with 
100 mM HCI. The sulllaydryl reagents, glutathione (GSH) and /3-mer- 
captoethanol (/3 ME), were added directly to the omeprazole at 0.25 M. 
After 20 rain, 20 /xl of the treated omeprazole was diluted into 1.25 ml 
YPD medium at pH 3.5 and the standard 24 h growth inhibition assay 
was performed. (C) Effects of /3-mercaptoethanol on the growth in- 
hibitory effects of acid-activated omeprazole. Aliquots (5 /xl) of acid- 
activated omeprazole were incubated with either 0. 1.25, 2.5, 3.75 or 5 ,al 
of 0.25 M /3-mercaptoethanol in a total volume of I0 /.tl. After 20 rain, 
the treated omeprazole was diluted into 0.675 ml YPD medium at pH 3.5 
and the standard growth inhibition assay was conducted, The final 
concentrations of /3-mercaptoethanol in wells containing 0.87 mM acid- 
activated omeprazole were 0, 0.375, 0.75, 1.125, and 1.5 raM, as 
indicated. 
amide of omeprazole is only moderately stable and can 
interact with non-essential accessible cysteine residues 
(such as those in the cell wall), populations of cells 
rendered partially viable recovered as the effective concen- 
tration of omeprazole declined with time. These data sug- 
gest that a majority of target(s) must be modified by 
omeprazole action before cell viability is significantly 
impaired. 
3.3. Correlating inhibition of in I'il,o proton pumping  with 
H +-ATPase actiui O, 
Glucose-dependent medium acidification provides a rel- 
ative measure of proton pumping by the plasma membrane 
H+-ATPase [23,26,33]. Fig. 4 shows the effect of acid- 
activated omeprazole on glucose-dependent proton pump- 
ing by SN236. Carbon-starved cells were incubated with 
the indicated amount of acid-activated omeprazole at pH 
4.5 for 10 rain prior to the addition of glucose. Glucose- 
dependent proton pumping was initiated at normal or near 
normal rates at all levels of omeprazole treatment, but the 
initial rate response gave way to a dose-dependent inhibi- 
tion of proton pumping. Acid-activated omeprazole at 
< 0.22 mM progressively inactivated proton pumping until 
a new steady state external pH was reached. At higher 
omeprazole concentrations, > 0.36 raM, proton pumping 
was progressively inhibited and a new low pH steady-state 
was not attained as the cells appeared to resorb protons 
from the medium. The inhibition profiles suggest that a 
specific catalytic intermediate may be required for interac- 
tion with omeprazole since the initial rate of pumping was 
essentially unaffected by the inhibitor treatments. Full 
inhibition of enzyme activity would likely be dependent on 
the rate of catalytic turnover, the half-time for the reactive 
intermediate, and the concentration of inhibitor. As ex- 
pected, inhibition of proton pumping was extensively (~ 
80%) blocked by pre-treatment of acid-activated omepra- 
zole with a slight excess of 2-mercaptoethanol, while 
DMSO and 2-mercaptoethanol added at equivalent concen- 
trations had no effect on pumping (not shown). 
Glucose-dependent proton pumping in S. cereuisiae is a 
complex process which requires glucose uptake, glucose 
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Fig. 3. The fungicidal activity of omeprazole at pH 3.5. Cells incubated 
with omeprazole in a standard growth assay for 20 h at pH 3.5 were 
diluted in YPD medium and plated on solid YPD medium in duplicate. 
The percentage cell viability was estimated as 100 X (percent plating 
efficiency of treated cells)/(percent plating efficiency of control cells not 
treated with omeprazole). Cell growth (D)  and viability (O)  are indi- 
cated. 
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Fig. 4. Omeprazole-induced inhibition of glucose-dependent proton 
pumping by S. cerecisiae. Effect of acid-activated omeprazole on the 
inhibition of glucose-dependent medium acidification. Acid-activation of 
omeprazole and glucose-induced medium acidification by strain SN236 
were carried out as described in Section 2. Acid-activated omeprazole 
was added in a maximum volume of 20 /~1. Cells were preincubated with 
acid-activated omeprazole at the indicated concentrations for 10 min prior 
to initiation of medium acidification with glucose. 
metabolism, and activation of the proton pump [34,35]. To 
establish whether inhibition of proton pumping by acid- 
activated omeprazole was due to a corresponding inhibi- 
tion of the H+-ATPase, identical batches of cells were 
treated with acid-activated omeprazole at varying concen- 
trations and assayed for glucose-induced medium acidifica- 
tion. Plasma membranes were isolated from the cells and 
the kinetic properties of the vanadate sensitive H+-ATPase 
assayed in vitro. Fig. 5 shows the strong correlation be- 
tween the extent of in vivo proton pumping after treatment 
with omeprazole and the residual activity of the plasma 
membrane ATPase recovered in the highly purified plasma 
membrane fraction• The loss of enzyme activity following 
in vivo omeprazole treatment is consistent with irreversible 
covalent modification of the ATPase. A partially-inhibited, 
omeprazole-treated enzyme showed a K0. 5 for ATP ~ 0.7 
mM and a vanadate K i ~ 0.5 /xM that were nearly identi- 
cal to non-inhibited control enzyme. The inhibition of 
H+-ATPase in omeprazole-treated cells was not due to 
glucose-depletion, which is known to inactivate the en- 
zyme but with different kinetic effects [36]. Collectively, 
these data are consistent with the H+-ATPase serving as a 
principal target for omeprazole-induced inhibition of cell 
growth and proton pumping. 
3.4. Site of action .[or omeprazole inhibition 
The reactive sulfenamide of omeprazole is not expected 
to cross the bilayer and therefore accessible cell surface 
and/or membrane sector sulfhydryl groups of the H +- 
ATPase are expected to be the principal site(s) modified. 
This notion was tested by analyzing the growth of wild 
type and pmal mutant cells at important cysteine residues. 
Three cysteine residues, C148, C312 and C867, are pre- 
dicted to lie either within or near the extracellular surface 
of transmembrane s gments 2, 3 and 10, respectively 
(these assignments are based on a topology model for the 
yeast H+-ATPase which incorporates ten transmembrane 
segments [2]). In YPD medium at pH 3.5, similar levels of 
omeprazole were required to inhibit the growth of wild 
type and pmal mutant strains carrying the C312S and 
C867A mutations (Fig. 6A). However, the C148S mutant 
was 2-3-times less sensitive than the wild type to omepra- 
zole. This result suggests that C148 in transmembrane 
segment 2 may be an important initial site of interaction 
with omeprazole. 
Transmembrane s gment 2 is believed to be part of a 
helical hairpin structure that is formed with transmembrane 
segment 1and a short linking turn region [19]. To examine 
whether this region significantly affects omeprazole inter- 
action, additional pmal mutants were analyzed in which 
cysteine residues were introduced into different regions of 
the hairpin structure. It was found that the introduction of a 
cysteine as M128C, a position on helix 1 predicted to be 
adjacent to C148 on helix 2, gave a 3-fold enhancement of 
growth sensitivity to omeprazole (Fig. 6). Interestingly, the 
introduction of a cysteine, G156C (isolated as a suppressor 
of GI58D [30]) near the C-terminus of helix 2, resulted in 
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Fig. 5. In vivo inhibition by omeprazole of glucose-dependent medium 
acidification and correlative ffects on H+-ATPase activity. Glucose-in- 
duced medium acidification was measured in 100 ml suspensions of 
SN236 cells (A595n m ~ 7.5) treated with the indicated amounts of acid- 
activated omeprazole for 10 min. Plasma membranes were isolated from 
the treated cells after a 30 min incubation with drug and the specific 
activity (/zmol P i /min per mg) of the associated H+-ATPase is indicated 
in parentheses. All activity measurements were performed on duplicate 
samples with less than 10% difference between like samples. The cell 
treatments were 0 omeprazole (,~), 0.36 mM omeprazole ([]), 0.72 mM 
omeprazole (~), 1.1 mM omeprazole (o). 
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a mutant enzyme that was significantly less sensitive to 
omeprazole than either the wild type or the C 148S mutant. 
The parent G158D mutant is pH sensitive and cannot be 
assayed under these conditions. However, it shows identi- 
cal behavior to the double mutant with other types of 
sulfhydryl-modifying reagents (not shown). These results 
confirm previous assertions that this region of the H +- 
ATPase is conformationally sensitive [19,20] and further 
suggest that the region around C148 is important for 
inhibition of the enzyme and hence, yeast cell growth. 
The differential effects of omeprazole on the growth of 
the cysteine-deficient pmal mutants were seen in both 
whole cell proton pumping assays and in determinations of 
plasma membrane-bound H+-ATPase activity in vitro. 
Analysis of glucose-dependent medium acidification by 
wild type and pmal mutant strains showed that strain 
C148S, but not strains C312S and C867A, was substan- 
tially resistant to omeprazole-induced inhibition (Fig. 6B). 
Although proton pumping was partially inhibited in the 
C148S mutant by 0.36 mM omeprazole, growth was barely 
affected at this concentration (Fig. 6A). This observation 
probably reflects the more extensive degradation of acti- 
vated omeprazole during growth assays, which were car- 
ried out over a much longer time-course than the proton 
pumping assays (24 h versus 40 min). When purified 
plasma membranes from the wild type and the C148S 
mutant were recovered after in vivo inhibition of proton 
pumping by omeprazole, a comparison of residual H ÷- 
ATPase activities showed that the mutant enzyme was 
only modestly inhibited. This result correlated with the 
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Fig. 7. Comparative inhibition by omeprazole of medium acidification 
and H +-ATPase activity in C 148S. (A) In vivo inhibition by acid-activated 
omeprazole of glucose-dependent medium acidification and plasma mem- 
brane H+-ATPase activity of SN236 and C148S. Medium acidification 
was measured by point determinations of 100 ml cell suspensions of 
SN236 ([3, II) or C148S ((3, 0 )  that were either untreated (open 
symbols) or treated with 0.36 mM acid-activated omeprazole (closed 
symbols) for 10 min. Plasma membranes were isolated from treated cells 
after 30 rain and the residual plasma membrane H+-ATPase activity 
(/zmol Pi /min per mg) is indicated in the parentheses. Each activity 
represents he average obtained from duplicate xperiments, with repli- 
cates differing by less than 10%. 
limited omeprazole inhibition of proton pumping in the 
mutant cells (Fig. 7). In contrast, treatment of detergent-ex- 
tracted enzymes with omeprazole in vitro, at concentra- 
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Fig. 6. Effects of omeprazole on growth and glucose-dependent proton pumping in wild type and pmal mutant strains of S. ceret, isiae. (A) Effect of 
omeprazole on the growth of the wild type strain SN236 and pmal mutants altered in membrane sector amino acids. The pmal mutant strains examined 
contained the following mutations C 148S, C312S, C867A, M128C and G I58D/GI56C, as indicated. All strains were measured at pH 3.5 in the standard 
drug challenge growth assay described in Section 2. (B) Effect of acid-activated omeprazole on glucose-dependent medium acidification by SN236 and 
pmal mutants with altered membrane sector cysteine residues. Glucose-dependent proton pumping was measured in the presence and absence of 0.36 mM 
acid-activated omeprazole as described in Section 2. 
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tions several-fold below those required to inhibit the en- 
zyme in vivo, extensively inhibited both the wild type and 
pmal  mutant H+-ATPases (not shown). In fact, the ATP- 
ase from the C148S mutant was slightly more sensitive 
than the ATPase from the wild type strain. The in vitro 
sensitivity of the H÷-ATPase indicates that the enzyme 
contains additional omeprazole sensitive sites that are not 
accessible in vivo. Such sites are not without precedent 
and include three cytoplasmically located sulfhydryl 
groups, including an NEM-reactive site [37] within the 
ATP binding site. Consistent with a catalytic site origin for 
omeprazole inhibition in vitro, Mg-ATP was found to 
strongly protect the enzyme from inhibition (data not 
shown). This high affinity cytoplasmic inhibitory site is 
unlikely to be related to the site affected by omeprazole 
inhibition in vivo. 
4. Discussion 
An ideal antifungal target should be both essential to 
the cell and accessible to selective inhibitors that interact 
with the extracellular surface of the cell under acidic 
growth conditions. The plasma membrane H÷-ATPase of 
fungi has these attributes. The reagent omeprazole was 
chosen to probe the H+-ATPase as an antifungal target 
because conserved cysteine residues are located near the 
cell surface [2] and because the drug is activated under 
acidic conditions, forming a positively charged highly 
specific cysteine-reactive species that does not readily 
penetrate the lipid bilayer. Omeprazole interacts with cell 
surface residues of the H+,K÷-ATPase in the lumen of the 
parietal cell, irreversibly blocking gastric acidification and 
thereby aiding in the treatment of gastric ulcers [4,28]. We 
have shown that omeprazole inhibits the growth of the 
fungi S. cerevisiae and C. albicans in a pH-dependent 
manner between pH 2.5 and 4.5 and that there is stoichio- 
metric protection by /3-mercaptoethanol of growth inhibi- 
tion by acid-activated omeprazole at pH 3.5 (Figs. 1 and 
2), These data are consistent with the expected formation 
of a sulfenamide derivative as the active growth-inhibitory 
species. The inability of acid-activated omeprazole to in- 
hibit growth at pH 5.0 is consistent with the known 
instability and rapid deactivation of the sulfenamide at 
pH > 4.0 [29]. The primary growth-inhibiting target for 
omeprazole in S. cere~,isiae is the plasma membrane H+- 
ATPase, and the conserved residue C148 of transmem- 
brane segment 2 may be an important site of interaction. 
Several complementary lines of evidence support these 
conclusions. 
First, omeprazole blocks both growth and glucose-de- 
pendent proton pumping, and the inhibitory effect on 
proton pumping correlates with the relative activity of 
plasma membrane ATPase recovered from such cells (Fig. 
5). The residual glucose-activated H÷-ATPase activity re- 
covered from cells treated with omeprazole at a suboptimal 
level shows the expected ecrease in Vm~ x but no change 
in the K0. 5 for ATP or sensitivity to the inhibitor sodium 
vanadate was observed (Fig. 5). These data strongly sug- 
gest that the H +-ATPase is the principal target for omepra- 
zole-induced inhibition of cell growth while the systems 
responsible for either glucose uptake or the glucose-depen- 
dent regulation of the H +-ATPase are unaffected. 
Second, omeprazole inhibits yeast growth via cell sur- 
face sites, since the levels of omeprazole required to 
inhibit growth were several times greater than those needed 
to inhibit the plasma membrane ATPase in vitro. The 
active form of omeprazole is a positively charged sulfen- 
amide and is therefore unlikely to cross the plasma mem- 
brane. Any sulfenamide that crosses the membrane should 
be rapidly inactivated by the neutral cytoplasmic pH (pH 
~ 7.1) and by the presence of a significant concentration 
of intracellular glutathione. In addition, Mg-ATP strongly 
protects against he action of omeprazole in vitro, implying 
that the high affinity inhibitory site(s) observed under 
these conditions is cytoplasmically located. The well char- 
acterized NEM binding site in the ATP-binding region of 
the cytoplasmic kinase domain [37] is a likely site of 
omeprazole action on the in vitro treated enzyme. 
Third, omeprazole inhibition of in vivo proton pumping 
appears to require the enzyme to proceed through its 
reaction cycle, with omeprazole binding site becoming 
accessible during the reaction cycle (Fig. 4). This is consis- 
tent with the known modes of action of SCH28080 and 
ouabain on the gastric H+,K+-ATPase and the Na+,K +- 
ATPase, respectively. These drugs both favor the E2 en- 
zyme conformation of the ATPase for binding [3,5]. 
Fourth, the C148S mutation in the PMA1 gene makes 
S. cere~,isiae less sensitive to omeprazole inhibition of 
growth and glucose-dependent proton pumping, while the 
plasma membrane ATPase from cells treated with omepra- 
zole in vivo has a residual activity commensurate with the 
level of resistance shown by proton pumping (Fig. 7). The 
C148S mutant H+-ATPase is known to be present at a 
wild type level in the plasma membrane and displays a 
normal sensitivity to vanadate [18]. The differential sensi- 
tivities of the C148S mutant and wild type to omeprazole 
in growth assays occurred over a relatively narrow concen- 
tration range (Fig. 6A). This effect was expected since the 
reactive sulfenamide species should scavenge free -SH 
groups including exposed cysteine residues on the H +- 
ATPase, on other membrane proteins and in the cell wall. 
These data suggest hat in this concentration range, the 
H+-ATPase is the principal inhibitory target and that the 
C148 region may be an important initial site of interaction 
with omeprazole. Direct labeling studies and more detailed 
mutagenesis experiments are in progress to better assess 
this point. 
Inhibition of the H+-ATPase during glucose-dependent 
proton pumping appears to require catalytic turnover (Fig. 
4) which is consistent with a major conformational change 
occurring during the reaction cycle. While C148 of the 
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yeast plasma membrane ATPase is distant in primary 
sequence from the membrane sector residues (in the C- 
terminal portion) of gastric H+,K+-ATPase which cova- 
lently bind omeprazole and pantoprazole [4,5], omeprazole 
seems to bind to the same transmembrane loop as 
SCH28080 does in the gastric enzyme [15]. The binding of 
SCH28080 requires an E 2 conformation and is competi- 
tively affected by binding of K ÷. SCH28080 protects the 
gastric H+,K÷-ATPase against omeprazole binding, sug- 
gesting that the SCH28080 and omeprazole binding sites 
may partially overlap [5]. The differences in the amino 
acid targets between the yeast ATPase and in the gastric 
H+,K÷-ATPase does not exclude the possibility that com- 
parable loci are important for initial sulfenamide binding, 
with the ultimate effectiveness of the drug depending on 
covalent attachment toaccessible reactive cysteine residues. 
The present study adds to the growing body of evidence 
implicating transmembrane s gments 1and 2 of the fungal 
ATPase as conformationally important elements of the 
catalytic reaction cycle. Over 30 mutations mapping to this 
region have now been analyzed and most modify the 
function of the ATPase [2,19,20], The importance of C148 
to ATPase structure/function i  the region of transmem- 
brane segment 2 is consistent with the conservation of 
C148 [38]. Other mutations, M128C and G156C, GI58D 
which are expected to perturb the structure near C 148, also 
substantially modify the sensitivity of S. cereuisiae to 
omeprazole (Fig. 6A,B). The GI58D, G156C mutations 
probably alter the conformation or environment of trans- 
membrane segment 2 in S. cerec'isiae, restricting the ac- 
cessibility of C 148 to attack by the sulfenamide of omepra- 
zole. M128 and C148 are conserved residues predicted to 
lie on the same face of transmembrane s gments I and 2 
[19]. An M128C mutant enzyme is more sensitive to 
omeprazole than the wild-type enzyme (Fig. 6A). The 
M128C mutation could either provide a more accessible 
target or an enhanced function-altering target for the drug. 
Whether the introduced cysteine at M128 or the residue 
C148 is the principal target for drug action in this mutant 
has yet to be determined. 
The growth inhibitory and fungicidal effects of omepra- 
zole on S. cerecis iae suggests that the plasma membrane 
H' -ATPase could to be developed as a cell surface anti- 
fungal target. The conformationally active transmembrane 
segments 1 and 2 and the short intervening turn contain a 
number of important residues which are conserved among 
the fungi and which either deleteriously effect yeast growth 
or are lethal when genetically modified [19]. Such struc- 
tural constraints offer potential recognition and targeting 
features. Drugs targeted to this region do not have to cross 
the plasma membrane and therefore will not be susceptible 
to the action of multidrug resistance pumps [39]. An 
understanding of fungal plasma membrane proton pump 
structure and how the enzyme modulates cell growth will 
expedite the development of directed antifungal screening 
procedures and expand the possibilities for the rational 
design of agents directed at this novel cell surface target. 
This approach and the power of yeast molecular genetics 
have the potential to contribute to our understanding of the 
mode of action of existing therapeutics and simplify exper- 
imental approaches to the more general problem of P-type 
ATPase structure/function. It should also facilitate the 
development of new reagents that are targeted at other 
P-type ATPases, including those of other parasites and 
pathogens, and those differentially expressed in animal 
tissues. 
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